Maria E. Arcila

49.1k citations

253 papers · 15.7k indexed · 13 hit papers · h-index 60

Impact in

Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 0.1%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research

Papers in

Cancer Research 105
- Cancer Genomics and Diagnostics 97
Pulmonary and Respiratory Medicine 140
- Lung Cancer Treatments and Mutations 114

Co-authors: Marc Ladanyi Mark G. Kris Gregory J. Riely Vincent A. Miller William Pao Maureen F. Zakowski Camelia S. Sima Natasha Rekhtman
Journals: Journal of Clinical Oncology (55 papers)Clinical Cancer Research (23 papers)Journal of Thoracic Oncology (17 papers)Blood (16 papers)Journal of Molecular Diagnostics (14 papers)
Partner nations: United States Canada Japan

In The Last Decade

Maria E. Arcila

242 papers receiving 15.5k citations

Hit Papers

13 papers align trajectories log scale

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden 2019 · 289 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Clinical Cancer Research
2017 The American Journal of Surgical Pathology
2017 Journal of Molecular Diagnostics
2017 Cell stem cell
2016 The Lancet Oncology
2013 Clinical Cancer Research
2013 Molecular Cancer Therapeutics
2013 Clinical Cancer Research
2012 Cancer Discovery
2012 Clinical Cancer Research
2011 Clinical Cancer Research
2011 Journal of Clinical Oncology
2010 Clinical Cancer Research

Peers

Countries citing papers authored by Maria E. Arcila

Since Specialization

Citations

This map shows the geographic impact of Maria E. Arcila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria E. Arcila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria E. Arcila more than expected).

Fields of papers citing papers by Maria E. Arcila

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria E. Arcila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria E. Arcila. The network helps show where Maria E. Arcila may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Maria E. Arcila, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maria E. Arcila Line = papers co-authored together Maria E. Arcila links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions Clinical Cancer Research ·Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely	2021	47
2	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden Clinical Cancer Research ·Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason C. Chang, Darragh Halpenny, Alison M. Schram, Charles M. Rudin, David M. Hyman, Maria E. Arcila, Michael F. Berger, Ahmet Zehir, Mark G. Kris, Alexander Drilon, Marc Ladanyi Hit paper breakdown →	2019	289
3	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach Clinical Cancer Research ·Jason C. Chang, Deepu Alex, Matthew J. Bott, Kay See Tan, Venkatraman Seshan, Min-Min Lin, Jennifer L. Sauter, Darren J. Buonocore, Chad Vanderbilt, Sounak Gupta, Patrice Desmeules, Francis M. Bodd, Gregory J. Riely, Valerie W. Rusch, David R. Jones, Maria E. Arcila, William D. Travis, Marc Ladanyi, Natasha Rekhtman	2019	67
4	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers Clinical Cancer Research ·Michael Offin, Hira Rizvi, Megan Tenet, Ai Ni, Francisco Sánchez-Vega, Bob T. Li, Alexander Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus Schultz, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann	2018	230
5	Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer Clinical Cancer Research ·Ken Suzawa, Michael Offin, Daniel Lu, Evelyn Tubb, Morana Vojnic, Roger S. Smith, Joshua K. Sabari, Huichun Tai, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, William W. Lockwood, Alexander Drilon, Marc Ladanyi, Romel Somwar	2018	83
6	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance Clinical Cancer Research ·Helena A. Yu, Ken Suzawa, Emmet Jordan, Ahmet Zehir, Ai Ni, Hyunjae R. Kim, Mark G. Kris, Matthew D. Hellmann, Bob T. Li, Romel Somwar, David B. Solit, Michael F. Berger, Maria E. Arcila, Gregory J. Riely, Marc Ladanyi	2018	188
7	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer Clinical Cancer Research ·Kathryn C. Arbour, 钰庆李, Hyunjae R. Kim, Jordan Dienstag, Helena A. Yu, Francisco Sánchez-Vega, Piro Lito, Michael F. Berger, David B. Solit, Matthew D. Hellmann, Mark G. Kris, Charles M. Rudin, Ai Ni, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely	2017	317
8	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma Clinical Cancer Research ·Min Yuen Teo, Richard Bambury, Emily C. Zabor, Emmet Jordan, Hikmat Al‐Ahmadie, Mariel Elena Boyd, Nancy Bouvier, Stephanie A. Mullane, K. Eugene, Nitin Roper, Irina Ostrovnaya, David M. Hyman, Bernard H. Bochner, Maria E. Arcila, David B. Solit, Michael F. Berger, Dean F. Bajorin, Joaquim Bellmunt, Gopa Iyer, Jonathan E. Rosenberg	2017	189
9	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF Molecular Cancer Research ·Jaclyn F. Hechtman, Ahmet Zehir, Rona Yaeger, Lu Wang, Sumit Middha, Tao Zheng, David M. Hyman, David B. Solit, Maria E. Arcila, Laetitia Borsu, Jinru Shia, Efsevia Vakiani, Leonard B. Saltz, Marc Ladanyi	2015	43
10	Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches Clinical Cancer Research ·Alexander Drilon, Lu Wang, Maria E. Arcila, Sohail Balasubramanian, Joel Greenbowe, Jeffrey S. Ross, Phil Stephens, Doron Lipson, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Naiyer A. Rizvi	2015	202
11	MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking Clinical Cancer Research ·Maria E. Arcila, Alexander Drilon, Brooke E. Sylvester, Christine M. Lovly, Laetitia Borsu, Boris Reva, Mark G. Kris, David B. Solit, Marc Ladanyi	2014	106
12	Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders Cancer Discovery ·David M. Hyman, Eli L. Diamond, Cecile Rose T. Vibat, 黄佩刚, Jason C. Poole, Minal Patel, Veronica R. Holley, Goran Cabrilo, Timothy T. Lu, Maria E. Arcila, Young Rock Chung, Raajit K. Rampal, Mario E. Lacouture, Neal Rosen, Funda Meric‐Bernstam, José Baselga, Razelle Kurzrock, Mark G. Erlander, Filip Jankú, Omar Abdel‐Wahab	2014	84
13	EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics Molecular Cancer Therapeutics ·Maria E. Arcila, Khédoudja Nafa, Jamie E. Chaft, Natasha Rekhtman, Christopher Lau, Boris Reva, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi Hit paper breakdown →	2013	348
14	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR / KRA S and Presence of PIK3CA / AKT1 Mutations Clinical Cancer Research ·Natasha Rekhtman, Paul K. Paik, Maria E. Arcila, Laura J. Tafe, Geoffrey R. Oxnard, André L. Moreira, William D. Travis, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi	2012	289
15	Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions Clinical Cancer Research ·Yoshiyuki Suehara, Maria E. Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, Khidirov Jurabek, Alexander Drilon, Udayan Guha, Valerie W. Rusch, Mark G. Kris, Maureen F. Zakowski, Naiyer A. Rizvi, Raya Khanin, Marc Ladanyi	2012	132
16	Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling Molecular Cancer Therapeutics ·Jamie E. Chaft, Maria E. Arcila, Paul K. Paik, Christopher Lau, Gregory J. Riely, M. Catherine Pietanza, Maureen F. Zakowski, Valerie W. Rusch, Camelia S. Sima, Marc Ladanyi, Mark G. Kris	2011	162
17	Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations Journal of Clinical Oncology ·Paul K. Paik, Maria E. Arcila, Michael Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely Hit paper breakdown →	2011	503
18	EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma Clinical Cancer Research ·Mai He, Marzia Capelletti, Khédoudja Nafa, Cai‐Hong Yun, Maria E. Arcila, Vincent A. Miller, Michelle S. Ginsberg, Binsheng Zhao, Mark G. Kris, Michael J. Eck, Pasi A. Jänne, Marc Ladanyi, Geoffrey R. Oxnard	2011	109
19	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib Clinical Cancer Research ·Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, K Karydis, Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, Vincent A. Miller	2011	50
20	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation Clinical Cancer Research ·Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller Hit paper breakdown →	2010	485

About Maria E. Arcila

Maria E. Arcila is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Oncology, Hematology and Genetics, having authored 253 papers that have together received 15.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (114 papers), Cancer Genomics and Diagnostics (97 papers), Lung Cancer Research Studies (32 papers), Acute Myeloid Leukemia Research (26 papers), Colorectal Cancer Treatments and Studies (24 papers), Lymphoma Diagnosis and Treatment (21 papers), HER2/EGFR in Cancer Research (19 papers) and Genetic factors in colorectal cancer (15 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (10.6k citations), Oncology (8.7k citations), Cancer Research (4.7k citations), Pathology and Forensic Medicine (1.8k citations) and Genetics (927 citations). Maria E. Arcila has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Marc Ladanyi, Mark G. Kris, Gregory J. Riely, Vincent A. Miller, William Pao, Maureen F. Zakowski, Camelia S. Sima, Natasha Rekhtman, Helena A. Yu and Khédoudja Nafa. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Blood and Journal of Molecular Diagnostics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact